Insider Transactions in Q4 2023 at X4 Pharmaceuticals, Inc (XFOR)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 03
2023
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
39,906
-4.55%
|
$0
$0.9 P/Share
|
|
Nov 01
2023
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
199,531
-18.55%
|
$0
$0.73 P/Share
|
|
Nov 01
2023
|
Mark Baldry Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
10,257
-29.35%
|
$0
$0.73 P/Share
|
|
Nov 01
2023
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
67,695
-17.88%
|
$0
$0.73 P/Share
|
|
Nov 01
2023
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
230,645
-74.19%
|
$0
$0.73 P/Share
|
|
Nov 01
2023
|
Arthur Taveras Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
67,695
-21.35%
|
$0
$0.73 P/Share
|
|
Oct 31
2023
|
Mark Baldry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,947
+50.0%
|
-
|
|
Oct 31
2023
|
Adam S. Mostafa Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
230,645
+42.59%
|
-
|
|
Oct 31
2023
|
Mary Di Biase Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
230,645
+37.86%
|
-
|
|
Oct 31
2023
|
Paula Ragan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
532,081
+33.09%
|
-
|
|
Oct 31
2023
|
Arthur Taveras Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
230,645
+42.11%
|
-
|
|
Oct 16
2023
|
Keith Woods Director |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+50.0%
|
-
|